| Dallas Empey Ph.d., P.c. | |
|
459 N 300 W Suite 13 Kaysville UT 84037-4204 | |
| (801) 644-9244 | |
| (435) 656-3861 |
| Full Name | Dallas Empey Ph.d., P.c. |
|---|---|
| Speciality | Psychologist |
| Location | 459 N 300 W, Kaysville, Utah |
| Authorized Official Name and Position | Dallas Empey (PRESIDENT) |
| Authorized Official Contact | 8016449244 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Dallas Empey Ph.d., P.c. Po Box 31 Kaysville UT 84037-0031 Ph: (801) 644-9244 | Dallas Empey Ph.d., P.c. 459 N 300 W Suite 13 Kaysville UT 84037-4204 Ph: (801) 644-9244 |
| NPI Number | 1821391970 |
|---|---|
| Provider Enumeration Date | 12/13/2010 |
| Last Update Date | 12/16/2010 |
| Medicare PECOS PAC ID | 2961690821 |
|---|---|
| Medicare Enrollment ID | O20101220001028 |
News Archive
GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.
Researchers have long recognized that for learning and memory to take place, certain genes must be activated to alter neuron activity inside the brain.
A combination of two FDA-approved drugs, already approved for fighting other bacterial infections, shows potential for treating extensively drug resistant tuberculosis (XDR-TB), the most deadly form of the infection.
Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821391970 | NPI | - | NPPES |
| Provider Name | Dallas B Empey |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1316937410 PECOS PAC ID: 2769670520 Enrollment ID: I20101220001194 |
News Archive
GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.
Researchers have long recognized that for learning and memory to take place, certain genes must be activated to alter neuron activity inside the brain.
A combination of two FDA-approved drugs, already approved for fighting other bacterial infections, shows potential for treating extensively drug resistant tuberculosis (XDR-TB), the most deadly form of the infection.
Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.
› Verified 4 days ago
News Archive
GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.
Researchers have long recognized that for learning and memory to take place, certain genes must be activated to alter neuron activity inside the brain.
A combination of two FDA-approved drugs, already approved for fighting other bacterial infections, shows potential for treating extensively drug resistant tuberculosis (XDR-TB), the most deadly form of the infection.
Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.
› Verified 4 days ago
Kathryn Stewart, Ph.d. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 447 N 300 W, Suite 7, Kaysville, UT 84037 Phone: 801-544-7413 Fax: 801-544-3819 | |
Carbajal Counseling And Consulting, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 375 N Main St Ste 102, Kaysville, UT 84037 Phone: 801-989-3488 Fax: 801-989-5861 | |
Integrative Amd Holistic Center, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 375 N Main St Ste 202, Kaysville, UT 84037 Phone: 801-923-3290 | |
Healing Journey Counseling Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 475 N 300 W Ste 16, Kaysville, UT 84037 Phone: 385-381-2007 | |
Taylor And Taylor Consulting Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 459 N 300 W Ste 13, Kaysville, UT 84037 Phone: 801-337-9229 | |
Mountain West Psychology Services Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 265 N Main St Ste D173, Kaysville, UT 84037 Phone: 801-476-9616 Fax: 801-476-6990 | |
Hansann & Associates Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1470 S 500 E, Kaysville, UT 84037 Phone: 801-698-1160 |